Exploring Biosimilars in the Field of Breast Cancer
Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the role of biosimilars in the treatment of breast cancer.
Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the role of biosimilars in the treatment of breast cancer.
The cost of cancer treatments has become one of the biggest concerns to oncologists as they treat their patients, Litton says.
It is not ideal to send a patient into debt while they are being treated, and often times oncologists are making their decisions regarding treatment based off cost. Economic toxicity is a major issue in the field of breast cancer, as well as many other cancers, Litton notes.
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
April 20th 2024During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
